Which of the following is the best reason for a statistician to review the case report form prior to using it in a study?
Answer(s): A
The primary reason a statistician reviews the Case Report Form (CRF) is to ensure that the data being collected will support the planned statistical analyses for both safety and efficacy endpoints. According to the Good Clinical Data Management Practices (GCDMP, Chapter: CRF Design and Data Collection), CRF design should always align with the statistical analysis plan (SAP) to ensure that all necessary data elements are collected accurately and in analyzable formats. The statistician verifies that the CRF captures:All endpoints specified in the protocolProper derivation or calculation fieldsTiming of assessmentsConsistency across visits and formsOptions B, C, and D address secondary or technical design considerations but not the primary analytical purpose. The review ensures that the CRF provides a complete and analyzable dataset for meeting study objectives, regulatory submissions, and statistical integrity.
(CCDM-Verified Sources)SCDM GCDMP, Chapter: CRF Design and Data Collection, Section 4.4 Role of Statistics in CRF Design ICH E9 Statistical Principles for Clinical Trials, Section 5.2 Data Collection and Analysis AlignmentFDA Guidance for Industry: E6(R2) GCP, Section 5.1 Quality Management and Design Input from Stakeholders
Which Clinical Study Report section would be most useful for a Data Manager to review?
Answer(s): B
The section of the Clinical Study Report (CSR) that is most useful for a Data Manager is the one that includes the enumeration and explanation of data errors. This section provides a summary of the data quality control findings, including error rates, missing data summaries, and any issues identified during data review, validation, or database lock.According to the GCDMP (Chapter: Data Quality Assurance and Control), post-study reviews of data errors and quality findings are essential for evaluating process performance, identifying recurring issues, and informing continuous improvement in future studies. Other sections, such as clinical narratives (A) or statistical methods (C), are outside the core scope of data management responsibilities. The data error enumeration section directly reflects the quality and integrity of the data management process and is therefore the most relevant for review.
(CCDM-Verified Sources)SCDM GCDMP, Chapter: Data Quality Assurance and Control, Section 6.4 Quality Reporting and Error AnalysisICH E3 Structure and Content of Clinical Study Reports, Section 14.3 Data Quality Evaluation
ACME Intervention Co. is testing a new carotid artery stent in patients with coronary artery disease, in hopes of proving superiority over the current standard of care. After a subject signs consent, the surgeon enrolls the patient and retrieves information on which stent to use, but the surgeon does not share this information with the subject. Yesterday, the surgeon was instructed to use the control stent. Today, the surgeon has completed two surgeries: the first one the surgeon was instructed to use the control stent; the second one the surgeon was instructed to use the test stent. In what type of trial is the surgeon participating?
Answer(s): C
This scenario describes a single-blind trial, in which only one party--typically the subject--is unaware of the treatment assignment, while the investigator or surgeon knows which intervention is being administered.In this case, the surgeon receives instructions on which stent (test or control) to use, meaning they are aware of treatment allocation. However, the subject is blinded to which device is being implanted. This setup minimizes subject bias while maintaining procedural safety since the surgeon must know which product to use.Double-blind (A): Neither subject nor investigator knows the treatment. Open-label (B): Both subject and investigator know the treatment. Cross-over (D): Each subject receives both treatments in different periods. Thus, the correct answer is C. Single-blind, as only the participant remains blinded in this surgical device trial design.
(CCDM-Verified Sources)SCDM GCDMP, Chapter: Clinical Trial Phases and Protocols, Section 3.2 Study Blinding and Randomization ConceptsICH E6(R2) GCP, Section 1.10 Definition of Blinding/Masking FDA Guidance for Industry: Design Considerations for Pivotal Clinical Investigations for Medical Devices, Section 5.3 Blinding in Device Studies
A Data Manager is drafting a report for clinical operations staff for support in responding to questions about milestone-based site payments. Which is the most important information to display?
When reporting milestone-based site payment information, the most critical information to include is expected versus actual milestones met to date, by site. According to the Good Clinical Data Management Practices (GCDMP, Chapter: Project Management and Communication), effective reporting must support operational and financial decision-making by presenting performance indicators in a clear, actionable format. Site payments in clinical studies are typically tied to specific milestones such as subject enrollment, visit completion, or data cleaning achievements.By comparing expected (planned) versus actual (achieved) milestones per site, the Data Manager provides clinical operations staff with an accurate view of site progress and payment eligibility. This allows for identification of delayed sites, forecasting of upcoming payments, and early intervention for underperforming centers.While milestone summaries by month or type (options A and B) may be useful for trend analysis, they lack the operational detail required for financial tracking. Milestone data by patient (option D) is overly granular for site-level payment management.
(CCDM-Verified Sources)SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Project Management and Communication, Section 6.2 Data Reporting for Site Performance and Payments ICH E6 (R2) Good Clinical Practice, Section 5.18.4 Communication and Monitoring Reports FDA Guidance for Industry: Oversight of Clinical Investigations Site Management and Reporting
A data manager takes the INTERSECTION data in two tables wanting only the 50 records common to both tables. What operation did the data manager perform?
The inner join operation retrieves only the records that exist in both tables, which is the intersection of two datasets.In clinical data management, relational databases often store related data in multiple tables--for example, demographic data in one table and lab results in another. When a Data Manager needs to extract records that exist in both (e.g., subjects appearing in both demographics and labs), an inner join is used.According to the GCDMP (Chapter: Database Design and Build), joins are fundamental relational operations ensuring data consistency and integrity across multiple data domains. Inner join: Returns matching records from both tables (intersection). Left/right outer joins: Return all records from one table and matching records from the other (preserving nonmatches).Full outer join: Returns all records from both tables, whether matched or not. Therefore, to select only the 50 records common to both tables, the correct operation is an inner join.
(CCDM-Verified Sources)SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Design and Build, Section 4.3 Relational Database Concepts and JoinsICH E6 (R2) Good Clinical Practice, Section 5.5.3 Data Processing and Validation
Post your Comments and Discuss SCDM CCDM exam prep with other Community members:
Our website is free, but we have to fight against AI bots and content theft. We're sorry for the inconvenience caused by these security measures. You can access the rest of the CCDM content, but please register or login to continue.